Cargando…

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas

BACKGROUND: The polyamine-inhibitory regimen difluoromethylornithine (DFMO)+sulindac has marked efficacy in preventing metachronous colorectal adenomas. Polyamines are synthesised endogenously and obtained from dietary sources. Here we investigate dietary polyamine intake and outcomes in the DFMO+su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raj, K P, Zell, J A, Rock, C L, McLaren, C E, Zoumas-Morse, C, Gerner, E W, Meyskens, F L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593561/ https://www.ncbi.nlm.nih.gov/pubmed/23340449 http://dx.doi.org/10.1038/bjc.2013.15

Ejemplares similares

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas
por: Zell, Jason A., et al.
Publicado: (2012)

Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci
por: Ayoola, Moses B., et al.
Publicado: (2022)

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
por: El Naggar, Olivia, et al.
Publicado: (2022)

Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats
por: Madka, Venkateshwar, et al.
Publicado: (2023)

Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein
por: Lesnova, Ekaterina I., et al.
Publicado: (2021)

Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome
por: Stewart, Tracy Murray, et al.
Publicado: (2023)

Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways
por: Alhosin, Mahmoud, et al.
Publicado: (2020)

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
por: Saulnier Sholler, Giselle L., et al.
Publicado: (2015)

α-Difluoromethylornithine-Induced Cytostasis is Reversed by Exogenous Polyamines, Not by Thymidine Supplementation
por: Hyvönen, Mervi T., et al.
Publicado: (2021)

Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases
por: LoGiudice, Nicole, et al.
Publicado: (2018)

The Polyamine Inhibitor Alpha-Difluoromethylornithine Modulates Hippocampus-Dependent Function after Single and Combined Injuries
por: Rosi, Susanna, et al.
Publicado: (2012)

Differential preventive activity of sulindac and atorvastatin in Apc(+/Min-FCCC)mice with or without colorectal adenomas
por: Chang, Wen-Chi L, et al.
Publicado: (2018)

Maintenance DFMO Increases Survival in High Risk Neuroblastoma
por: Sholler, Giselle L. Saulnier, et al.
Publicado: (2018)

Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC
por: Faux, Maree C., et al.
Publicado: (2022)

Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas
por: Levin, Victor A, et al.
Publicado: (2018)

Therapy of murine squamous cell carcinomas with 2-difluoromethylornithine
por: Chen, Yan, et al.
Publicado: (2004)

Amine Containing Analogs of Sulindac for Cancer Prevention
por: Mathew, Bini, et al.
Publicado: (2018)

Oxazole and thiazole analogs of sulindac for cancer prevention
por: Mathew, Bini, et al.
Publicado: (2018)

Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO
por: Diccianni, Mitchell B., et al.
Publicado: (2020)

MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)

ETMR-18. TARGETING Lin28 IN ETMR WITH ODC1 INHIBITOR DFMO
por: Goodyke, Austin, et al.
Publicado: (2020)

Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development
por: Davis, Jennifer S., et al.
Publicado: (2020)

Sulindac for stroke treatment: neuroprotective mechanism and therapy
por: Modi, Jigar Pravinchandra, et al.
Publicado: (2014)

Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas
por: Romano, Robert, et al.
Publicado: (2017)

Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines
por: Boon, E M J, et al.
Publicado: (2004)

Deletion analysis of chromosome 8p in sporadic colorectal adenomas.
por: Cunningham, C., et al.
Publicado: (1994)

Gender Predilection in Sporadic Parathyroid Adenomas
por: Yavropoulou, Maria P., et al.
Publicado: (2020)

Structural Insight into DFMO Resistant Ornithine Decarboxylase from Entamoeba histolytica: An Inkling to Adaptive Evolution
por: Preeti,, et al.
Publicado: (2013)

Induction and Prevention of Gastric Cancer with Combined Helicobacter Pylori and Capsaicin Administration and DFMO Treatment, Respectively
por: Aziz, Faisal, et al.
Publicado: (2020)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

Metastasis of hormone-independent breast cancer to lung and bone is decreased by α-difluoromethylornithine treatment
por: Richert, Monica M, et al.
Publicado: (2005)

Sulindac metabolites inhibit epidermal growth factor receptor activation and expression
por: Pangburn, Heather A, et al.
Publicado: (2005)

DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27(Kip1) activity in neuroblastoma
por: KOOMOA, DANA-LYNN T., et al.
Publicado: (2013)

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma
por: Lewis, Elizabeth C., et al.
Publicado: (2020)

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma
por: Kraveka, Jacqueline M., et al.
Publicado: (2022)

Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer
por: Janakiram, Naveena B., et al.
Publicado: (2016)

Inhibiting Cycloxygenase and Ornithine Decarboxylase by Diclofenac and Alpha-Difluoromethylornithine Blocks Cutaneous SCCs by Targeting Akt-ERK Axis
por: Arumugam, Aadithya, et al.
Publicado: (2013)

Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress
por: Marchetti, Maria, et al.
Publicado: (2009)

Sulindac Prevents Esophageal Adenocarcinomas Induced by Gastroduodenal Reflux in Rats
por: Kim, Sung Wook, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_p7v9493cqsb1efqkr8pa1mhmqc